MARKET

VTYX

VTYX

VENTYX BIOSCIENCES INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.73
-0.03
-0.19%
After Hours: 15.73 0 0.00% 16:00 01/14 EST
OPEN
15.33
PREV CLOSE
15.76
HIGH
15.96
LOW
14.21
VOLUME
70.59K
TURNOVER
--
52 WEEK HIGH
26.00
52 WEEK LOW
13.95
MARKET CAP
791.16M
P/E (TTM)
-9.1374
1D
5D
1M
3M
1Y
5Y
Ventyx Biosciences Announces First Patient Dosed In Phase 2 Clinical Trial Of VTX002 For Treatment Of Moderate-To-Severe Ulcerative Colitis
Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx" or the "Company"), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory
Benzinga · 12/06/2021 13:02
Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis
VTX002 is an oral, peripherally-restricted, selective sphingosine 1 phosphate receptor 1 (S1P1) receptor modulator internally discovered and developed by the team at VentyxENCINITAS, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasda...
GlobeNewswire · 12/06/2021 13:00
BRIEF-Ventyx Biosciences Reports Q3 Net Loss Per Share Attributable To Common Shareholders $3.17
reuters.com · 11/17/2021 22:46
Ventyx Biosciences reports Q3 results
Ventyx Biosciences (NASDAQ:VTYX): Q3 Net Loss of $12.8M Cash, cash equivalents and marketable securities of $142M Press Release
Seekingalpha · 11/17/2021 21:42
Ventyx Biosciences Q3 EPS $(3.17) Up From $(3.58) YoY
Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(3.17) per share. This is a 11.45 percent increase over losses of $(3.58) per share from the same period last year.
Benzinga · 11/17/2021 21:19
Evercore ISI Group Initiates Coverage On Ventyx Biosciences with Outperform Rating, Announces Price Target of $50
Evercore ISI Group analyst Josh Schimmer initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Outperform rating and announces Price Target of $50.
Benzinga · 11/15/2021 13:58
Jefferies Initiates Coverage On Ventyx Biosciences with Buy Rating, Announces Price Target of $30
Jefferies analyst Michael Yee initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Buy rating and announces Price Target of $30.
Benzinga · 11/15/2021 11:58
Piper Sandler Initiates Coverage On Ventyx Biosciences with Overweight Rating, Announces Price Target of $50
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Overweight rating and announces Price Target of $50.
Benzinga · 11/15/2021 10:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VTYX. Analyze the recent business situations of VENTYX BIOSCIENCES INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VTYX stock price target is 42.50 with a high estimate of 50.00 and a low estimate of 30.00.
High50.00
Average42.50
Low30.00
Current 15.73
EPS
Actual
Estimate
-2.54-1.90-1.27-0.63
Q3 2020
Q4 2020
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 50.30M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Chief Executive Officer/Founder/Director/Primary Contact
Raju Mohan
Chief Scientific Officer
John Nuss
Vice President - Operations
Kathy Ogilvie
Executive Officer
Richard Gregg
Executive Officer
Chris Krueger
No Data
About VTYX
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet medical need. Its pipeline includes VTX958, VTX002, VTX2735 and Preclinical NLRP3 Inhibitor Portfolio. The Company’s lead product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor to address a range of immune-mediated diseases, such as psoriasis, inflammatory bowel disease (IBD), psoriatic arthritis and lupus. It is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 (S1P1R) modulator for ulcerative colitis (UC). The Company is also developing a NOD-like receptor protein 3 (NLRP3) inhibitors to address multiple indications driven by NLRP3 inflammasome activation. Its NLRP3 inhibitor and VTX2735 designed to treat systemic inflammatory diseases such as cardiovascular, hepatic, renal, and rheumatologic diseases.

Webull offers kinds of Ventyx Biosciences Inc stock information, including NASDAQ:VTYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTYX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTYX stock methods without spending real money on the virtual paper trading platform.